GlassScriptPhysician profile
Derek T Rainwater
NPI 1548767437
$4,075.07
in general payments reported to CMS, 2019-2025
26 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.00 · 2023: $418 · 2024: $2,393 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926 · Travel and Lodging: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.38 |
| Travel and Lodging | $1,096.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,539.57 | 2023-2025 | Minimed 780g |
| Novo Nordisk INC | $309.73 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $309.13 | 2023-2025 | |
| Corcept Therapeutics | $298.80 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $226.23 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $197.89 | 2023-2025 | Omnipod |
| Lilly USA, LLC | $184.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $170.07 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $147.14 | 2024-2025 | Repatha, Tepezza, Evenity |
| Tandem Diabetes Care, INC. | $117.88 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $69.00 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $65.97 | 2024 | |
| Sanofi-Aventis U.S. LLC | $64.48 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.23 | 2024-2025 | Jardiance, Synjardy |
| Sequel Med Tech, LLC | $45.17 | 2025 | Twiist |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.89 | 2021-2025 | |
| Abbott Laboratories | $37.20 | 2023-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $29.78 | 2023 | Tepezza |
| E.R. Squibb & Sons, L.L.C. | $29.08 | 2021 | |
| Neurocrine Biosciences, INC. | $23.54 | 2025 | |
| Recordati_rare_diseases_inc. | $22.38 | 2025 | Isturisa |
| Nevro Corp. | $19.52 | 2023 | Senza |
| Novartis Pharmaceuticals Corporation | $18.66 | 2024 | |
| Cequr Corporation | $17.92 | 2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $15.80 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $14.90 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Rainwater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.